A Cross-sectional cohort study of teprotumumab in subjects with thyroid eye disease
Latest Information Update: 03 Dec 2021
Price :
$35 *
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- 03 Dec 2021 New trial record
- 01 Nov 2021 Primary endpoint (Change in proptosis 2 mm) has been met, as per results published in the Ophthalmic Plastic and Reconstructive Surgery.
- 01 Nov 2021 Results published in the Ophthalmic Plastic and Reconstructive Surgery.